AbCellera Biologics Inc.
ABCL
Peringkat dalam Saham
#4228
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the... AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Harga Saham
$11.65
Kapitalisasi Pasar
$3.77B
Perubahan (1 hari)
-2.39%
Perubahan (1 tahun)
98.72%
Negara
CA
Perdagangan AbCellera Biologics Inc. (ABCL)
Kategori
Healthcare
Rasio P/B untuk AbCellera Biologics Inc. (ABCL)
Rasio P/B per October 2026 TTM: 4.22
Menurut laporan keuangan dan harga saham terbaru dari AbCellera Biologics Inc., rasio P/B saat ini (TTM) adalah 4.22. Pada akhir 2023, rasio P/B perusahaan adalah 1.43.
Riwayat rasio P/B untuk AbCellera Biologics Inc. dari 2018 hingga 2026
Rasio P/B pada akhir setiap tahun
| Tahun | Rasio P/B | Mengubah |
|---|---|---|
| 2026 (TTM) | 4.22 | 414.44% |
| 2024 | 0.82 | -43.01% |
| 2023 | 1.43 | -38.80% |
| 2022 | 2.34 | -39.10% |
| 2021 | 3.84 | -70.56% |
| 2020 | 13.06 | -98.53% |
| 2019 | 885.28 | 15.51% |
| 2018 | 766.43 | 0.00% |
Rasio P/B untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/B | Perbedaan Rasio P/B | Negara |
|---|---|---|---|
| 6.251 | 48.18% |
US
|
|
| 13.2547 | 214.21% |
US
|
|
| 4.208 | -0.25% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | 46.56% |
NL
|
